Inland Glaucoma Center

10/10/2026

https://youtu.be/xNTypbZ7_Rw

A new glaucoma laser got more than 8 in 10 patients off their daily...

09/09/2026

Can glaucoma still get worse even when your eye pressure reads normal? Yes, it can.

Glaucoma is a disease of the optic nerve, not just a number on a pressure check. Some patients develop progressive optic nerve damage even when their eye pressure has never tested above the traditional normal range of about 10 to 21 mmHg, a pattern called normal tension glaucoma.

What matters most is your individualized target eye pressure: the level that is low enough to protect your particular optic nerve.

Dr. Robert Gunzenhauser explains why in our latest blog post: https://inlandglaucomacenter.com/can-glaucoma-get-worse-even-when-eye-pressure-is-normal.html

09/08/2026

Calculate your glaucoma risk

09/06/2026

Are your glaucoma drops turning your eyes red?

Not every red eye is an infection or seasonal allergy. Daily glaucoma drops themselves can cause toxic or allergic conjunctivitis. The preservatives and active ingredients in the drops can irritate the surface of the eye, causing redness, burning, itching, and tearing that gets worse the longer the drops are used. Brimonidine and drops preserved with benzalkonium chloride are frequent culprits.

The good news is that lowering eye pressure no longer has to mean a lifetime of drops. Selective laser trabeculoplasty (SLT) is a gentle in-office laser treatment that lowers pressure at its source, and minimally invasive glaucoma surgery (MIGS) can lower pressure during cataract surgery or as a standalone procedure. For many patients these options mean fewer drops, and for some, no drops at all.

If your eyes are always red and you use glaucoma drops, ask us whether a drop-free option is right for you.

Inland Glaucoma Center, Upland, CA
Call 909-315-6891
Learn more: https://inlandglaucomacenter.com/selective-laser-trabeculoplasty.html
Se habla espanol

08/30/2026

Why can a normal eye pressure reading still miss glaucoma? Eye pressure often peaks overnight, the one time no one is measuring it. New research published this month traced the biology behind the nighttime rise. Our latest article by Dr. Marc Shomer explains what this means for patients with glaucoma or suspected glaucoma, and how specialists look past a single office reading with pressure profiles, OCT imaging, and visual field testing.

Read it here: https://inlandglaucomacenter.com/why-a-normal-eye-pressure-reading-can-miss-glaucoma.html

08/30/2026

New on our blog: Rhopressa (netarsudil), a newer type of glaucoma eye drop. It is the first Rho kinase inhibitor approved for glaucoma in the United States. Instead of reducing the fluid the eye makes, it helps the eye's own drainage system work better. Dr. Marc Shomer explains how it works, what the ROCKET trials showed, and the side effects to know about, including why eye redness is so common.

Read the full article:

Rhopressa (netarsudil 0.02%) is the first Rho kinase inhibitor eye drop for glaucoma. How it works, how much it lowers eye pressure, and its most common side effects.

07/13/2026

https://inlandglaucomacenter.com/the-glaucoma-doctor-blog/f/latanoprost-one-tiny-eye-drop-that-has-changed-glaucoma-care

07/03/2026

By Robert Gunzenhauser, MD: Your vision matters. At Inland Glaucoma Center, we're committed to delivering expert, compassionate eye care to help preserve your sight. Learn more about our advanced glaucoma treatments and comprehensive services by visiting your website today. Discover how our dedicated team supports your journey to better eye health.

https://inlandglaucomacenter.com/the-glaucoma-doctor-blog/f/when-should-you-take-timolol-or-dorzolamide%E2%80%93timolol-eye-drops

07/02/2026

https://inlandglaucomacenter.com/the-glaucoma-doctor-blog/f/glaucoma-premium-cataract-lenses

By Robert Gunzenhauser, MD

07/02/2026

A new large retrospective study published in Investigative Ophthalmology & Visual Science raises an important question about commonly prescribed calcium channel blockers and glaucoma progression.

Researchers reviewed electronic health record data from more than 7,400 patients with mild to moderate primary open angle glaucoma. After matching patients for factors such as age, s*x, race, ethnicity, and hypertension, they found that patients taking calcium channel blockers had a higher rate of progression to severe glaucoma compared with similar patients not taking these medications.

The association was seen with both major types of calcium channel blockers. Dihydropyridine calcium channel blockers were linked to a 67 percent higher relative risk of progression, while nondihydropyridine calcium channel blockers were associated with more than a threefold higher risk.

This does not prove that these medications cause glaucoma to worsen. The study had important limitations, including reliance on diagnosis codes and lack of detailed eye pressure, visual field, medication adherence, and treatment duration data.

The take home message is not to stop blood pressure or heart medications. These medications can be very important and should only be changed after discussion with the prescribing doctor or cardiologist.

However, for patients with glaucoma who are taking calcium channel blockers, this study suggests they may benefit from closer monitoring for signs of progression.

Medical education only. This is not personal medical advice.